Mechanisms underlying the anti-inflammatory effects of the Ca2+/calmodulin antagonist CV-159 in cultured vascular smooth muscle cells

Journal of Pharmacological Sciences

Volumn 113, Issue 3, 2010, Pages 214-223

  Usui, Tatsuya ^a   Yamawaki, Hideyuki ^a   Kamibayashi, Masato ^b   Okada, Muneyoshi ^a   Hara, Yukio ^a  

^a KITASATO UNIVERSITY   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Calmodulin; Dihydropyridine derivative; Inflammation; Signal transduction; Vascular smooth muscle

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 4 (3 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID 3 METHYL 5 [6 (5 PHENYL 3 PYRAZOLYLOXY)HEXYL] ESTER; 2 MORPHOLINO 8 PHENYLCHROMONE; ACETYLCYSTEINE; ANTIOXIDANT; CALMODULIN; DICHLORODIHYDROFLUORESCEIN DIACETATE; N (6 AMINOHEXYL) 5 CHLORO 1 NAPHTHALENESULFONAMIDE; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; PROTEIN KINASE B; PYRROLIDINE DITHIOCARBAMATE; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTERY MUSCLE; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; FLUOROMETRY; INFLAMMATION; MALE; MESENTERIC ARTERY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; WESTERN BLOTTING;

EID: 77954992702     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10100FP     Document Type: Article

References (41)

1. Umekawa H, Yamakawa K, Nunoki K, Taira N, Tanaka T, Hidaka H. Inhibition of calmodulin function by CV-159, a novel dihydropyridine compound. Biochem Pharmacol. 1988;37:3377-3381.
2. Imai H, Matsui K, Ochi S, Nakazawa M, Nakagawa Y, Imai S. Effects of the new dihydropyridine derivative 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 6-(5-phenyl-3-pyrazolyloxy)hexyl ester on the cardiohemodynamics and the energy metabolism of ischemic myocardium. Arzneimittelforschung. 1987;37:1348-1352.
3. Kamibayashi M. CV-159. Drugs Fut. 1989;14:206-210.
4. Miyazaki H, Tanaka S, Fujii Y, Shimizu K, Nagashima K, Kamibayashi M, et al. Neuroprotective effects of a dihydropyridine derivative, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarbox ylic acid methyl 6-(5-phenyl-3-pyrazolyloxy) hexyl ester (CV-159), on rat ischemic brain injury. Life Sci. 1999;64:869-878.
5. Kobayashi HP, Watanabe T, Oowada S, Hirayama A, Nagase S, Kamibayashi M, et al. Effect of CV159-Ca(2+)/calmodulin blockade on redox status hepatic ischemia-reperfusion injury in mice evaluated by a newly developed in vivo EPR imaging technique. J Surg Res. 2008;147:41-49.
6. Watanabe T, Oowada S, Kobayashi HP, Kamibayashi M, Ishiuchi A, Jinnouchi Y, et al. The role of the new Ca2+ antagonist, CV159, in hepatic I/R injury-the evaluation of hepatic organ reducing activity using in vivo and ex vivo EPR. J Surg Res. 2008;145:49-56.
7. Henry PD, Bentley KI. Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest. 1981; 68:1366-1369.
8. Bernini F, Catapano AL, Corsini A, Fumagalli R, Paoletti R. Effects of calcium antagonists on lipids and atherosclerosis. Am J Cardiol. 1989;64:129I-133I;discussion 133I-134I.
9. Henry PD. Atherogenesis, calcium and calcium antagonists. Am J Cardiol. 1990;66:3I-6I.
10. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
11. Libby P. Inflammation in atherosclerosis. Nature. 2002;420: 868-874.
12. Fan J, Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb. 2003;10:63-71.
13. Elahi MM, Matata BM. Free radicals in blood: evolving concepts in the mechanism of ischemic heart disease. Arch Biochem Biophys. 2006;450:78-88.
14. Usui T, Yamawaki H, Kamibayashi M, Okada M, Hara Y. CV-159, a unique dihydropyridine derivative, prevents TNF-induced inflammatory responses in human umbilical vein endothelial cells. J Pharmacol Sci. 2010;113:182-191.
15. Lai YM, Fukuda N, Su JZ, Suzuki R, Ikeda Y, Takagi H, et al. Novel mechanisms of the antiproliferative effects of amlodipine in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertens Res. 2002;25:109-115.
16. Soe NN, Ishida T, Ishida M, Sawano M, Abe K, Miho N, et al. Nifedipine interferes with migration of vascular smooth muscle cells via inhibition of Pyk2-Src axis. J Atheroscler Thromb. 2009;16:230-238.
17. Yamawaki H, Saito K, Okada M, Hara Y. Methylglyoxal mediates vascular inflammation via JNK and p38 in human endothelial cells. Am J Physiol Cell Physiol. 2008;295:C1510-C1517.
18. Yamawaki H, Hara N, Okada M, Hara Y. Visfatin causes endothelium-dependent relaxation in isolated blood vessels. Biochem Biophys Res Commun. 2009;383:503-508.
19. Abramoff MD, Magelhaes PJ, Ram SJ. Image Processing with ImageJ. Biophotonics International. 2004;11:36-42.
20. Kavurma MM, Khachigian LM. ERK, JNK, and p38 MAP kinases differentially regulate proliferation and migration of phenotypically distinct smooth muscle cell subtypes. J Cell Biochem. 2003;89:289-300.
21. Sotoudeh M, Li YS, Yajima N, Chan CC, Tsou TC, Wang Y, et al. Induction of apoptosis in vascular smooth muscle cells by mechanical stretch. Am J Physiol Heart Circ Physiol. 2002;282: 1709-1716.
22. Bayat H, Xu S, Pimentel D, Cohen RA, Jiang B. Activation of thromboxane receptor upregulates interleukin (IL)-1beta-induced VCAM-1 expression through JNK signaling. Arterioscler Thromb Vasc Biol. 2008;28:127-134.
23. Lee EJ, Kim DI, Kim WJ, Moon SK. Naringin inhibits matrix metalloproteinase-9 expression and AKT phosphorylation in tumor necrosis factor-alpha-induced vascular smooth muscle cells. Mol Nutr Food Res. 2009;53:1582-1591.
24. Lee CW, Lin CC, Luo SF, Lee HC, Lee IT, Aird WC, et al. Tumor necrosis factor-alpha enhances neutrophil adhesiveness: induction of vascular cell adhesion molecule-1 via activation of Akt and CaM kinase II and modifications of histone acetyltransferase and histone deacetylase 4 in human tracheal smooth muscle cells. Mol Pharmacol. 2008;73:1454-1464.
25. López-Franco O, Hernández-Vargas P, Ortiz-Muñoz G, Sanjuán G, Suzuki Y, Ortega L, et al. Parthenolide modulates the NFkappaB-mediated inflammatory responses in experimental atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:1864-1870.
26. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol. 1998;18:842-851.
27. Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, et al. The expression of the adhesion molecules ICAM-1, VCAM- 1, PECAM, and E-selectin in human atherosclerosis. J Pathol. 1993;171:223-229.
28. Dansky HM, Barlow CB, Lominska C, Sikes JL, Kao C, Weinsaft J, et al. Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage. Arterioscler Thromb Vasc Biol. 2001;21:1662-1667.
29. Orr AW, Hastings NE, Blackman BR, Wamhoff BR. Complex regulation and function of the inflammatory smooth muscle cell phenotype in atherosclerosis. J Vasc Res. 2010;47:168-180.
30. Naito Y, Shimozawa M, Manabe H, Nakabe N, Katada K, Kokura S, et al. Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species. Eur J Pharmacol. 2006;546: 11-18.
31. Wu L, Iwai M, Li Z, Li JM, Mogi M, Horiuchi M. Nifedipine inhibited angiotensin II-induced monocyte chemoattractant protein 1 expression: involvement of inhibitor of nuclear factor kappa B kinase and nuclear factor kappa B-inducing kinase. J Hypertens. 2006;24:123-130.
32. Kim SR, Bae YH, Bae SK, Choi KS, Yoon KH, Koo TH, et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta. 2008;1783:886-895.
33. Liu SL, Lin X, Shi DY, Cheng J, Wu CQ, Zhang YD. Reactive oxygen species stimulated human hepatoma cell proliferation via cross-talk between PI3-K/PKB and JNK signaling pathways. Arch Biochem Biophys. 2002;406:173-182.
34. Li JM, Fan LM, Christie MR, Shah AM. Acute tumor necrosis factor alpha signaling via NADPH oxidase in microvascular endothelial cells: role of p47phox phosphorylation and binding to TRAF4. Mol Cell Biol. 2005;25:2320-2330.
35. Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cui TX, et al. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension. 2004;43: 263-269.
36. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999;6748:82-85.
37. Grozinger CM, Schreiber SL. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol. 2002;9:3-16.
38. Backs J, Song K, Bezprozvannaya S, Chang S, Olson EN. CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J Clin Invest. 2006;116:1853-1864.
39. Little GH, Bai Y, Williams T, Poizat C. Nuclear calcium/calmodulin-dependent protein kinase IIdelta preferentially transmits signals to histone deacetylase 4 in cardiac cells. J Biol Chem. 2007;282:7219-7231.
40. Inoue K, Kobayashi M, Yano K, Miura M, Izumi A, Mataki C, et al. Histone deacetylase inhibitor reduces monocyte adhesion to endothelium through the suppression of vascular cell adhesion molecule-1 expression. Arterioscler Thromb Vasc Biol. 2006;26: 2652-2659.
41. Luo SF, Chang CC, Lee IT, Lee CW, Lin WN, Lin CC, et al. Activation of ROS/NF-kappaB and Ca2+/CaM kinase II are necessary for VCAM-1 induction in IL-1beta-treated human tracheal smooth muscle cells. Toxicol Appl Pharmacol. 2009;237:8-21.